A
Angela C. Doran
Researcher at Pfizer
Publications - 24
Citations - 1333
Angela C. Doran is an academic researcher from Pfizer. The author has contributed to research in topics: Circadian rhythm & Chemistry. The author has an hindex of 15, co-authored 20 publications receiving 1211 citations.
Papers
More filters
Journal ArticleDOI
The impact of p-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/ 1b knockout mouse model
Angela C. Doran,R. Scott Obach,Bill J. Smith,Natilie Hosea,Stacey L. Becker,Ernesto Callegari,Cuiping Chen,Xi Chen,Edna F. Choo,Julie Cianfrogna,Loretta M. Cox,John P. Gibbs,Megan A. Gibbs,Heather L. Hatch,Cornelis E. C. A. Hop,Ilana N. Kasman,Jennifer L. LaPerle,JianHua Liu,Xingrong Liu,Michael J. Logman,Debra Maclin,Frank M. Nedza,Frederick R. Nelson,Emily R. Olson,Sandhya Rahematpura,David Raunig,Sabrinia Rogers,Kari Schmidt,Douglas K. Spracklin,Mark A. Szewc,Matthew D. Troutman,Elaine E. Tseng,Meihua Tu,Jeffrey Van Deusen,Karthik Venkatakrishnan,Gary Walens,Ellen Q. Wang,Diane Wong,Adam Yasgar,Chenghong Zhang +39 more
TL;DR: It appears that most CNS-active agents demonstrate at least some P-gp-mediated transport that can affect brain concentrations, and unbound plasma concentrations may need to be greater than values projected using receptor affinity data to achieve adequate receptor occupancy for effect.
Journal ArticleDOI
Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding
Xingrong Liu,Bill J. Smith,Cuiping Chen,Ernesto Callegari,Stacey L. Becker,Xi Chen,Julie Cianfrogna,Angela C. Doran,Shawn D. Doran,John P. Gibbs,Natilie Hosea,JianHua Liu,Frederick R. Nelson,Mark A. Szewc,Jeffery Van Deusen +14 more
TL;DR: The present study demonstrates that rapid brain equilibration requires a combination of high BBB permeability and low brain tissue binding, and the strategy to select compounds with rapid brain Equilibration in drug discovery should identify compounds with highBBB permeable and low nonspecific binding in brain tissue.
Journal ArticleDOI
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period.
Kevin M. Walton,Katherine Fisher,David M. Rubitski,Michael Marconi,Qing-Jun Meng,Martin Sládek,Jessica Adams,Michael Bass,Rama Y. Chandrasekaran,Butler Todd W,Matt Griffor,Francis Rajamohan,Megan Serpa,Yuhpyng Chen,Michelle Claffey,Michael H. Hastings,Andrew S. I. Loudon,Elizabeth S. Maywood,Jeffrey F. Ohren,Angela C. Doran,Travis T. Wager +20 more
TL;DR: characterized 3-(3-chloro-phenoxymethyl)-1-(tetrahydro-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin- 4-ylamine (PF-4800567), a novel and potent inhibitor of CK1ϵ with greater than 20-fold selectivity over CK1δ that should prove useful in probing unique roles between these two kinases in multiple signaling pathways
Journal ArticleDOI
Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.
Xingrong Liu,Bill J. Smith,Cuiping Chen,Ernesto Callegari,Stacey L. Becker,Xi Chen,Julie Cianfrogna,Angela C. Doran,Shawn D. Doran,John P. Gibbs,Natilie Hosea,JianHua Liu,Frederick R. Nelson,Mark A. Szewc,Jeffrey Van Deusen +14 more
TL;DR: For quick brain penetration with simple diffusion mechanism compounds, CCSF and Cu,plasma represent Cu,brain equally well; for efflux substrates or slow brain penetration compounds,CCSF appears to be equivalent to or more accurate than Cu, Plasma to representCu,brain.
Journal ArticleDOI
3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators : Hit-to lead and lead optimization
Allen J. Duplantier,Ivan Viktorovich Efremov,John Candler,Angela C. Doran,Alan H. Ganong,Jessica A. Haas,Ashley N. Hanks,Kenneth G. Kraus,John T. Lazzaro,Jiemin Lu,Noha Maklad,Sheryl A. McCarthy,Theresa J. O’Sullivan,Bruce N. Rogers,Judith A. Siuciak,Douglas K. Spracklin,Lei Zhang +16 more
TL;DR: Human microsomal clearance and suboptimal physicochemical properties of the initial lead were improved to give potent, metabolically stable and orally available mGluR2 PAMs.